Mirus was founded in 1995 to address the limitations and risks of viral gene transfer. We developed the first pDNA transfection method that combined high efficiency with low cellular toxicity, and since that time, we’ve focused on applying intentional design to …

Mirus Bio LLC (formerly Mirus Bio Corporation), develops and manufactures transfection reagents, electroporation solutions and related products for life science research.

Mar 26, 2024 · Since its founding in 1995, Mirus Bio has been meeting industry and customer needs through innovation, collaboration and partnerships.

May 22, 2024 · Merck, a leading science and technology company, has signed a definitive agreement to acquire life science company Mirus Bio for US$ 600 million (around € 550 million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

A high efficiency electroporation solution compatible with most conventional electroporation devices including Lonza-Amaxa®, Bio-Rad® or Harvard BTX®. Delivers CRISPR/Cas9 components in the following formats: DNA – Deliver plasmid DNA expressing Cas9 or guide RNA; mRNA – Deliver messenger RNA expressing Cas9

Aug 1, 2024 · Mirus Bio’s leading GMP transfection reagents complement company’s upstream bioprocessing portfolio; Combined portfolio meets customer needs as demand for novel modalities grows

May 22, 2024 · Mirus Bio’s transfection reagents strengthen Merck’s upstream portfolio; Acquisition will advance Merck’s ambition to provide a fully integrated and comprehensive solution for viral vector manufacturing; Reinforces Merck’s continued commitment to shaping the future of gene therapies and other novel modalities

Under Dale’s guidance, Mirus Bio has become a trusted name in cell and gene therapy, developing innovative technologies that enable efficient and effective delivery of genetic material into cells. His strategic vision and commitment to scientific excellence have positioned Mirus Bio as a frontrunner in the cell and gene therapy industry.

Aug 2, 2024 · Germany-based Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities. The companies entered a definitive agreement in May 2024 under which Merck’s Life Science business in the US and Canada, MilliporeSigma, would acquire Mirus Bio.

May 23, 2024 · Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at around $600 million.